1. Willicombe M, Brookes P, Sergeant R, Santos-Nunez E, Steggar C, Galliford J, et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation. 2012; 94:172–177. PMID:
22735711.
2. Carta P, Di Maria L, Caroti L, Buti E, Antognoli G, Minetti EE. Anti-human leukocyte antigen DQ antibodies in renal transplantation: Are we underestimating the most frequent donor specific alloantibodies? Transplant Rev (Orlando). 2015; 29:135–138. PMID:
25976621.
3. Tambur AR, Leventhal JR, Zitzner JR, Walsh RC, Friedewald JJ. The DQ barrier: improving organ allocation equity using HLA-DQ information. Transplantation. 2013; 95:635–640. PMID:
23288109.
4. Lomago J, Jelenik L, Zern D, Howe J, Martell J, Zeevi A, et al. How did a patient who types for HLA-B
*4403 develop antibodies that react with HLA-B
*4402? Hum Immunol. 2010; 71:176–178. PMID:
19963027.
5. Cecka JM, Reed EF, Zachary AA. HLA high-resolution typing for sensitized patients: a solution in search of a problem? Am J Transplant. 2015; 15:855–856. PMID:
25778678.
6. Baxter-Lowe LA, Cecka M, Kamoun M, Sinacore J, Melcher ML. Center-defined unacceptable HLA antigens facilitate transplants for sensitized patients in a multi-center kidney exchange program. Am J Transplant. 2014; 14:1592–1598. PMID:
24934640.